The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (1) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (1).

##STR00001##

The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (1) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (1).

##STR00001##

An organic positive electrode active material for aqueous redox flow batteries, and more particularly, to technology of applying an organic positive electrode active material to make up for the drawbacks of conventional aqueous redox flow batteries. An aqueous redox flow battery to which a particular positive electrode active material is applied has no problems regarding metal deposition, and can also be useful in realizing a high energy density because the positive electrode active material may be used at high concentration due to an increase in solubility in a solvent, attaining a high working voltage, and enhancing energy efficiency. Also, the aqueous redox flow battery has excellent economic feasibility because an expensive organic electrolyte is not used.

An organic positive electrode active material for aqueous redox flow batteries, and more particularly, to technology of applying an organic positive electrode active material to make up for the drawbacks of conventional aqueous redox flow batteries. An aqueous redox flow battery to which a particular positive electrode active material is applied has no problems regarding metal deposition, and can also be useful in realizing a high energy density because the positive electrode active material may be used at high concentration due to an increase in solubility in a solvent, attaining a high working voltage, and enhancing energy efficiency. Also, the aqueous redox flow battery has excellent economic feasibility because an expensive organic electrolyte is not used.

Described are methods of dephosphorylation. Methods of dephosphorylation include contacting a phosphate containing substrate with one or more CeO.sub.2 nanocrystal. Also described is modifying the pH of the dephosphorylation reaction to affect the amount and rate of dephosphorylation. Further described are methods of making CeO.sub.2 nanocrystals of the present disclosure.

Described are methods of dephosphorylation. Methods of dephosphorylation include contacting a phosphate containing substrate with one or more CeO.sub.2 nanocrystal. Also described is modifying the pH of the dephosphorylation reaction to affect the amount and rate of dephosphorylation. Further described are methods of making CeO.sub.2 nanocrystals of the present disclosure.

The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

The present disclosure relates to HIF-2? inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2? scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.